281 related articles for article (PubMed ID: 33009167)
1. Access to Healthcare and Harm Reduction Services During the COVID-19 Pandemic for People Who Use Drugs.
Stowe MJ; Calvey T; Scheibein F; Arya S; Saad NA; Shirasaka T; Dannatt L; Ghosh A; Yee A; Ratta-Apha W; Vadivel R; Siste K; Shah B; Ramalho R; Narasimha VL; Delic M; Peyron E; Onoria JLG; Pant SB; Boujraf S; Grandinetti P; Morgan N
J Addict Med; 2020 Dec; 14(6):e287-e289. PubMed ID: 33009167
[TBL] [Abstract][Full Text] [Related]
2. The Changing Landscape of Alcohol Use and Alcohol Use Disorder During the COVID-19 Pandemic - Perspectives of Early Career Professionals in 16 Countries.
Calvey T; Scheibein F; Saad NA; Shirasaka T; Dannatt L; Stowe MJ; Shah B; Narasimha VL; Bruschi A; Peyron E; Gumikiriza-Onoria JL; Ghosh A; Pant SB; Yee A; Ratta-Apha W; Vadivel R; Siste K; Maiti T; Boujraf S; Grandinetti P; Morgan N; Arya S
J Addict Med; 2020 Dec; 14(6):e284-e286. PubMed ID: 32909983
[TBL] [Abstract][Full Text] [Related]
3. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report.
Crowley D; Delargy I
Harm Reduct J; 2020 Jul; 17(1):49. PubMed ID: 32680520
[TBL] [Abstract][Full Text] [Related]
4. The impact of COVID-19 on access to harm reduction, substance use treatment and recovery services in Scotland: a qualitative study.
Schofield J; Dumbrell J; Matheson C; Parkes T; Bancroft A
BMC Public Health; 2022 Mar; 22(1):500. PubMed ID: 35287630
[TBL] [Abstract][Full Text] [Related]
5. Opioid Use Disorder and COVID-19: Crashing of the Crises.
Khatri UG; Perrone J
J Addict Med; 2020; 14(4):e6-e7. PubMed ID: 32404651
[TBL] [Abstract][Full Text] [Related]
6. Innovation During COVID-19: Improving Addiction Treatment Access.
Samuels EA; Clark SA; Wunsch C; Jordison Keeler LA; Reddy N; Vanjani R; Wightman RS
J Addict Med; 2020; 14(4):e8-e9. PubMed ID: 32404652
[TBL] [Abstract][Full Text] [Related]
7. Harm reduction during the COVID-19 outbreak in Iran.
Karimi-Sari H; Sharafi H; Rezaee-Zavareh MS; Alavian SM
Lancet Psychiatry; 2020 Aug; 7(8):e57. PubMed ID: 32711718
[No Abstract] [Full Text] [Related]
8. Commentary on the coronavirus pandemic: Anticipating a fourth wave in the opioid epidemic.
McCann Pineo M; Schwartz RM
Psychol Trauma; 2020 Aug; 12(S1):S108-S110. PubMed ID: 32496102
[TBL] [Abstract][Full Text] [Related]
9. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
Uscher-Pines L; Sousa J; Raja P; Mehrotra A; Barnett M; Huskamp HA
J Subst Abuse Treat; 2020 Nov; 118():108124. PubMed ID: 32893047
[TBL] [Abstract][Full Text] [Related]
10. Challenges of methadone maintenance treatment during the COVID-19 epidemic in China: Policy and service recommendations.
Jiang H; Su H; Zhang C; Liu X; Li R; Zhong N; Zhao M
Eur Neuropsychopharmacol; 2020 Jun; 35():136-137. PubMed ID: 32307223
[No Abstract] [Full Text] [Related]
11. Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic.
Dunlop A; Lokuge B; Masters D; Sequeira M; Saul P; Dunlop G; Ryan J; Hall M; Ezard N; Haber P; Lintzeris N; Maher L
Harm Reduct J; 2020 May; 17(1):26. PubMed ID: 32375887
[TBL] [Abstract][Full Text] [Related]
12. Harm reduction via online platforms for people who use drugs in Russia: a qualitative analysis of web outreach work.
Davitadze A; Meylakhs P; Lakhov A; King EJ
Harm Reduct J; 2020 Dec; 17(1):98. PubMed ID: 33298081
[TBL] [Abstract][Full Text] [Related]
13. Integrating harm reduction and clinical care: Lessons from Covid-19 respite and recuperation facilities.
Kimmel SD; Bazzi AR; Barocas JA
J Subst Abuse Treat; 2020 Nov; 118():108103. PubMed ID: 32972644
[TBL] [Abstract][Full Text] [Related]
14. Ensuring Access to Crisis Services During COVID-19.
Balfour ME; Curtis A; Miller AH
Psychiatr Serv; 2020 Nov; 71(11):1208. PubMed ID: 33135602
[No Abstract] [Full Text] [Related]
15. Toward a human-centered use of technology: a stakeholder analysis of harm reduction and CBO staff.
Aronson ID; Bennett AS; Freeman R
Harm Reduct J; 2020 Oct; 17(1):77. PubMed ID: 33076911
[TBL] [Abstract][Full Text] [Related]
16. Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia.
Roxburgh A; Jauncey M; Day C; Bartlett M; Cogger S; Dietze P; Nielsen S; Latimer J; Clark N
Harm Reduct J; 2021 Feb; 18(1):20. PubMed ID: 33596940
[TBL] [Abstract][Full Text] [Related]
17. Protecting Access To Abortion During The COVID-19 Pandemic.
Sackeim MG
Health Aff (Millwood); 2020 Aug; 39(8):1456-1458. PubMed ID: 32744933
[TBL] [Abstract][Full Text] [Related]
18. Treatment for Anxiety and Substance Use Disorders During the COVID-19 Pandemic: Challenges and Strategies.
Satre DD; Iturralde E; Ghadiali M; Young-Wolff KC; Campbell CI; Leibowitz AS; Sterling SA
J Addict Med; 2020 Dec; 14(6):e293-e296. PubMed ID: 33156267
[TBL] [Abstract][Full Text] [Related]
19. Calls for Access to Safe Injecting Supplies as a Critical Public Health Measure During the COVID-19 Pandemic.
Chayama KL; Ng C; McNeil R
J Addict Med; 2020; 14(5):e142-e143. PubMed ID: 32769778
[TBL] [Abstract][Full Text] [Related]
20. Utilization of telehealth services during the COVID-19 pandemic.
Hoyer P; Ahatov R; Ross L
Cutis; 2020 Aug; 106(2):70-71. PubMed ID: 32941560
[No Abstract] [Full Text] [Related]
[Next] [New Search]
